Order Article Reprints

Konikoff T, Yanai H, Libchik D, Avni-Biron I, Snir Y, Banai H, Broytman Y, Dotan I, Ollech JE. Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data. Journal of Clinical Medicine. 2023; 12(13):4488. https://doi.org/10.3390/jcm12134488

Konikoff, Tom, Henit Yanai, Dror Libchik, Irit Avni-Biron, Yifat Snir, Hagar Banai, Yelena Broytman, Iris Dotan, and Jacob E. Ollech. 2023. "Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data" Journal of Clinical Medicine 12, no. 13: 4488. https://doi.org/10.3390/jcm12134488

Konikoff, T., Yanai, H., Libchik, D., Avni-Biron, I., Snir, Y., Banai, H., Broytman, Y., Dotan, I., & Ollech, J. E. (2023). Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data. Journal of Clinical Medicine, 12(13), 4488. https://doi.org/10.3390/jcm12134488